Riociguat

CHEMBL2107834 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

422.4 g/mol

LogP

1.6

Phase

4

Riociguat is a soluble guanylate cyclase (sGC) stimulator that acts by two distinct mechanisms: sensitizing sGC to endogenous nitric oxide (NO) and directly stimulating sGC independently of NO, thereby increasing cyclic GMP production in vascular smooth muscle and causing vasodilation and antiproliferative effects. It is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

分子量

422.4000 g/mol

LogP

1.60

TPSA

138.00 Å²

リピンスキーの五則

適合

治療領域

Cardiovascular Disease Respiratory Disease Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Migraine Infectious Disease Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hypertension Heart Failure

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N

InChI

InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)

Molecular Formula

C20H19FN8O2

HBD / HBA

2 / 9

回転可能結合数

5

重原子数

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Riociguat is a soluble guanylate cyclase (sGC) stimulator that acts by two distinct mechanisms: sensitizing sGC to endogenous nitric oxide (NO) and directly stimulating sGC independently of NO, thereby increasing cyclic GMP production in vascular smooth muscle and causing vasodilation and antiproliferative effects. It is approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Yes, Riociguat is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2107834. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11304743. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Riociguat PillFYIで

構造

クイックデータ

分子式: C20H19FN8O2
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.